Lesley Russell - 11 Mar 2026 Form 4 Insider Report for ENANTA PHARMACEUTICALS INC (ENTA)

Role: Director
Signature: /s/ Matthew Kowalsky as attorney-in-fact
Issuer symbol: ENTA
Transactions as of: 11 Mar 2026
Net transactions value: $0
Form type: 4
Filing time: 13 Mar 2026, 16:19:48 UTC
Previous filing: 14 Mar 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Russell Lesley	Director	C/O ENANTA PHARMACEUTICALS, INC., 4 KINGSBURY AVENUE, WATERTOWN	/s/ Matthew Kowalsky as attorney-in-fact	13 Mar 2026	0001374636

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ENTA	Stock Option (right to buy)	Award		+20,000		$0.000000^*	20,000	11 Mar 2026	Common Stock	20,000	$14.17	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (March 11, 2026), with the final monthly installment vesting no later than the nearest trading day on the Nasdaq Global Select Market preceding the 2027 annual meeting of stockholders.